INDEPENDENCE CONTRACT DRILLI (ICD)
US4534156066 - Common Stock
Overall ICD gets a fundamental rating of 1 out of 10. We evaluated ICD against 59 industry peers in the Energy Equipment & Services industry. ICD may be in some trouble as it scores bad on both profitability and health. ICD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ICD has reported negative net income.
ICD had a positive operating cash flow in the past year.
In the past 5 years ICD always reported negative net income.
Of the past 5 years ICD 4 years had a positive operating cash flow.
1.2 Ratios
ICD has a Return On Assets of -15.80%. This is amonst the worse of the industry: ICD underperforms 92.06% of its industry peers.
With a Return On Equity value of -37.58%, ICD is not doing good in the industry: 87.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ICD has grown nicely.
Looking at the Gross Margin, with a value of 32.59%, ICD is in the better half of the industry, outperforming 65.08% of the companies in the same industry.
ICD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ICD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% |
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
2. Health
2.1 Basic Checks
ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICD has been increased compared to 1 year ago.
ICD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ICD has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.26, we must say that ICD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.26, ICD is doing worse than 88.89% of the companies in the same industry.
ICD has a debt to FCF ratio of 10.37. This is a negative value and a sign of low solvency as ICD would need 10.37 years to pay back of all of its debts.
ICD has a Debt to FCF ratio (10.37) which is in line with its industry peers.
A Debt/Equity ratio of 1.08 is on the high side and indicates that ICD has dependencies on debt financing.
ICD has a Debt to Equity ratio of 1.08. This is in the lower half of the industry: ICD underperforms 79.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Altman-Z | -1.26 |
ROIC/WACCN/A
WACC2.02%
2.3 Liquidity
A Current Ratio of 1.33 indicates that ICD should not have too much problems paying its short term obligations.
ICD has a worse Current ratio (1.33) than 79.37% of its industry peers.
A Quick Ratio of 1.28 indicates that ICD should not have too much problems paying its short term obligations.
ICD has a worse Quick ratio (1.28) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
The earnings per share for ICD have decreased strongly by -662.07% in the last year.
The Revenue for ICD has decreased by -21.60% in the past year. This is quite bad
The Revenue has been growing by 8.06% on average over the past years. This is quite good.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
3.2 Future
The Earnings Per Share is expected to decrease by -46.50% on average over the next years. This is quite bad
Based on estimates for the next years, ICD will show a decrease in Revenue. The Revenue will decrease by -8.70% on average per year.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ICD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICD is valued a bit cheaper than the industry average as 74.60% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than ICD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.54 | ||
| EV/EBITDA | 4.69 |
4.3 Compensation for Growth
ICD's earnings are expected to decrease with -46.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ICD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INDEPENDENCE CONTRACT DRILLI
NYSE:ICD (8/28/2024, 8:04:00 PM)
After market: 0.555 -0.03 (-5.26%)0.5858
-0.06 (-9.88%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change-99.95%
Ins Owners75.82%
Ins Owner Change-1.2%
Market Cap8.92M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.05 | ||
| P/FCF | 0.54 | ||
| P/OCF | 0.21 | ||
| P/B | 0.06 | ||
| P/tB | 0.06 | ||
| EV/EBITDA | 4.69 |
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% | ||
| FCFM | 9.24% |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Debt/EBITDA | 4.57 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 14.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 116% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -1.26 |
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%